Abeona Therapeutics (ABEO) Short term Debt (2010 - 2026)

Abeona Therapeutics' Short term Debt history runs 13 years deep, the most recent figure standing at $13.3 million for Q1 2026.

• In Q1 2026, Short term Debt rose 63.64% year-over-year to $13.3 million; the TTM figure through Mar 2026 stood at $13.3 million (up 63.64% YoY), while the FY2025 annual figure was $12.2 million, up 106.24% from the prior year.
• Short term Debt was $13.3 million for Q1 2026 at Abeona Therapeutics, up from $12.2 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $13.3 million in Q1 2026 to a low of $2.2 million in Q2 2024.
• Historically, Short term Debt has averaged $6.8 million across 4 years, with a median of $5.6 million in 2025.
• Biggest YoY gain for Short term Debt was 757.56% in 2022; the steepest drop was 75.4% in 2022.
• A 4-year view of Short term Debt shows it stood at $4.9 million in 2022, then grew by 20.42% to $5.9 million in 2024, then surged by 106.24% to $12.2 million in 2025, then advanced by 9.09% to $13.3 million in 2026.
• The last three Short term Debt figures came in at $13.3 million (Q1 2026), $12.2 million (Q4 2025), and $8.9 million (Q3 2025), per Business Quant data.